ir.amicusrx.com
Investor Relations - Amicus TherapeuticsThe Investor Relations website contains information about Amicus Therapeutics business for stockholders, potential investors, and financial analysts.
http://ir.amicusrx.com/
The Investor Relations website contains information about Amicus Therapeutics business for stockholders, potential investors, and financial analysts.
http://ir.amicusrx.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Tuesday
LOAD TIME
0.8 seconds
PAGES IN
THIS WEBSITE
9
SSL
EXTERNAL LINKS
19
SITE IP
206.200.251.19
LOAD TIME
0.828 sec
SCORE
6.2
Investor Relations - Amicus Therapeutics | ir.amicusrx.com Reviews
https://ir.amicusrx.com
The Investor Relations website contains information about Amicus Therapeutics business for stockholders, potential investors, and financial analysts.
ir.amicusrx.com
Investor Relations - Amicus Therapeutics
http://ir.amicusrx.com/index.cfm
Welcome from Chairman and CEO. Epidermolysis Bullosa (EB) Program. Patient Advocacy at Amicus. Grants and Charitable Donations. Annual Reports and Proxies. Sign Up for Email Alerts. Annual Reports and Proxies. Sign Up for Email Alerts. A passionate team with a purpose. As a monotherapy for Fabry disease, SD-101. For Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) products for Fabry disease, Pompe disease, and other Lysosomal Storage Disorders. Apr 6, 2017. Apr 3, 2017.
Amicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study (NASDAQ:FOLD)
http://ir.amicusrx.com/releasedetail.cfm?ReleaseID=1019744
Apr 3, 2017. Amicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study. Target Exceeded with More than 160 Patients Enrolled. Top-Line Data on Track for 3Q17. CRANBURY, N.J. April 03, 2017. Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, has completed enrollment in the ongoing Phase 3 clinical study (ESSENCE) of the novel topical medicine SD-101 for patients with all 3 major types of epidermolysis bullosa (EB).
Barclays Global Healthcare Conference 2017 - Amicus Therapeutics
http://ir.amicusrx.com/eventdetail.cfm?EventID=180612
Welcome from Chairman and CEO. Epidermolysis Bullosa (EB) Program. Patient Advocacy at Amicus. Grants and Charitable Donations. Annual Reports and Proxies. Sign Up for Email Alerts. Annual Reports and Proxies. Sign Up for Email Alerts. Barclays Global Healthcare Conference 2017. Mar 14, 2017.
Corporate Governance - Amicus Therapeutics
http://ir.amicusrx.com/corporate-governance.cfm
Welcome from Chairman and CEO. Epidermolysis Bullosa (EB) Program. Patient Advocacy at Amicus. Grants and Charitable Donations. Annual Reports and Proxies. Sign Up for Email Alerts. Annual Reports and Proxies. Sign Up for Email Alerts. Essential Governance Documents and Committees Charters.
SEC Filings - Amicus Therapeutics
http://ir.amicusrx.com/sec.cfm
Welcome from Chairman and CEO. Epidermolysis Bullosa (EB) Program. Patient Advocacy at Amicus. Grants and Charitable Donations. Annual Reports and Proxies. Sign Up for Email Alerts. Annual Reports and Proxies. Sign Up for Email Alerts. All Filings (excluding Section 16). Apr 3, 2017. Mar 13, 2017. Statement of beneficial ownership. Mar 8, 2017. Mar 3, 2017. Campbell, bradley l. Mar 3, 2017. Mar 1, 2017. Mar 1, 2017. Feb 16, 2017. Feb 16, 2017. Feb 15, 2017. 10 results per page. 25 results per page.
TOTAL PAGES IN THIS WEBSITE
9
INDUSTRY SPONSORED SYMPOSIA | SSIEM
http://www.ssiem2016.org/industry-sponsored-symposia
Eur District and Congress Venue. PARALLEL SESSIONS AND UPDATE LECTURES. NUTRITION AND ADULT GROUP SESSIONS. MEET THE EXPERT SESSIONS. We wish to acknowledge the generous financial support by holding a sponsored session during the 2016 SSIEM Annual Symposium of the companies listed below:. Monday September 5 th , 18.30-20.00 Red Room. The complexities of adult PKU: Case discussions. A MacDonald, UK. JC Rocha, Portugal. G Wilcox, UK. A Burlina, Italy. F Feillet, France. M Pasquali, USA. N Longo, USA. Impro...
Amicus Therapeutics: Advancing Therapies to Treat Rare Diseases
http://www.amicusrx.com/posters.aspx
Welcome from Chairman and CEO. Posters, Abstracts, and Publications. Patient Advocacy at Amicus. Educational Grants and Charitable Contributions. Posters, Abstracts, and Publications. Germain D.P., et al., The New England Journal of Medicine. Treatment of Fabry Disease with the Pharmacologic Chaperone Migalastat. Society for Pediatric Dermatology Annual Meeting July 2016. Efficacy and Safety Results From a Phase 2b Dose-ranging Study of SD-101 cream in Patients With Epidermolysis Bullosa. American Societ...
Amicus Therapeutics: Advancing Therapies to Treat Rare Diseases
http://www.amicusrx.com/pompe.aspx
Welcome from Chairman and CEO. Posters, Abstracts, and Publications. Patient Advocacy at Amicus. Educational Grants and Charitable Contributions. We are leveraging our biologics and Chaperone-Advanced Replacement Therapy (CHART ). Pompe disease is an inherited Lysosomal Storage Disorder (LSD) caused by a deficiency of the enzyme acid alpha-glucosidase (GAA). Reduced or absent levels of GAA lead to the accumulation of the substrate glycogen in the lysosomes of muscles and other tissues. In 2013, we comple...
Amicus Therapeutics: Advancing Therapies to Treat Rare Diseases
http://www.amicusrx.com/protein.aspx
Welcome from Chairman and CEO. Posters, Abstracts, and Publications. Patient Advocacy at Amicus. Educational Grants and Charitable Contributions. Science that’s powered by passion. Posters, Abstracts, and Publications. Disruption of cellular function; and.
Amicus Therapeutics: Advancing Therapies to Treat Rare Diseases
http://www.amicusrx.com/fabry.aspx
Welcome from Chairman and CEO. Posters, Abstracts, and Publications. Patient Advocacy at Amicus. Educational Grants and Charitable Contributions. As a monotherapy, migalastat is an investigational oral, small molecule drug designed to bind to and stabilize the endogenous alpha-Gal A that is made in the patient’s own cells, to enable its trafficking (i.e., as a pharmacological chaperone ) to lysosomes. For more information, view our mechanism of disease video. And Fabry disease infographic. If approved, w...
Amicus Therapeutics: Advancing Therapies to Treat Rare Diseases
http://www.amicusrx.com/welcome.aspx
Welcome from Chairman and CEO. Posters, Abstracts, and Publications. Patient Advocacy at Amicus. Educational Grants and Charitable Contributions. Welcome from Chairman and CEO. Welcome to Amicus Therapeutics. How do we take that perspective and build it into every part of the business? What would be a meaningful advancement or a risk I would take? We do more than say that we are patient focused we live it. All the best,. John F. Crowley. Chairman and Chief Executive Officer Amicus Therapeutics Inc.
Amicus Therapeutics: Advancing Therapies to Treat Rare Diseases
http://www.amicusrx.com/belief.aspx
Welcome from Chairman and CEO. Posters, Abstracts, and Publications. Patient Advocacy at Amicus. Educational Grants and Charitable Contributions. In 2005, the employees of Amicus crafted a belief statement that would encompass our core values and remind us of the reason we do what we do every day. Welcome from Chairman and CEO. We believe.in the fight. To remain at the forefront of therapies for rare and orphan diseases. We support the disease communities - and their families. We take smart risks. We bui...
Amicus Therapeutics: Advancing Therapies to Treat Rare Diseases
http://www.amicusrx.com/general.aspx
Welcome from Chairman and CEO. Posters, Abstracts, and Publications. Patient Advocacy at Amicus. Educational Grants and Charitable Contributions. Fabry Disease: General Disease Information. For more information, view our mechanism of disease video. And download our Fabry disease awareness brochure. And Fabry disease infographic. Patient Advocacy at Amicus. Educational Grants and Charitable Contributions. Epidermolysis Bullosa: General Disease Information. Pompe Disease: General Disease Information.
Amicus Therapeutics: Advancing Therapies to Treat Rare Diseases
http://www.amicusrx.com/patient.aspx
Welcome from Chairman and CEO. Posters, Abstracts, and Publications. Patient Advocacy at Amicus. Educational Grants and Charitable Contributions. Patient Advocacy at Amicus. Welcome to Amicus Patient and Professional Advocacy. Listening and learning from individuals and their families affected by these diseases;. Searching for new and better therapies;. Incorporating patient input into the design of clinical trials for those therapies as our research advances through the drug development process; and.
TOTAL LINKS TO THIS WEBSITE
19
American Midstream Partners, LP - Investor Relations
Main Pass Oil Gathering. Quivira and Burns Point. AMID K-1 Tax Information. JPE K-1 Tax information. Investor and Media Relations. FERC Reporting and Hotlines. Main Pass Oil Gathering. Quivira and Burns Point. AMID K-1 Tax Information. JPE K-1 Tax information. Investor and Media Relations. FERC Reporting and Hotlines. 29/03/18 04:02 PM ET. American Midstream Announces Southcross Unitholder Approval of Merger. American Midstream Reports Fourth Quarter and Full Year 2017 Results. Powered By Q4 Inc.
ir.americanrealtycapitalproperties.com
IRWeblink
Thank you for your interest in IR Solutions. You have reached this page because the URL you have requested is no longer available, or you do not have permission to view it. For more information on the most comprehensive IR web site management tool available, please click here. If you have any questions, e-mail IRSupport@snl.com. Or call (866) 802-9128 and ask for an IR Solutions sales representative. To return to the main SNL Financial homepage.
American Renal
Skip to main content. Home and Peritoneal Dialysis. Take good care of the patients and the financial success will follow. Enable the nephrologist to practice as he/she sees appropriate. Provide the nephrologist the autonomy to make operational decisions. Acknowledge that facility staff members are a critical and valuable asset. Do everything possible to hire and retain the best possible staff. Listen to the practitioners and provide the tools needed to take excellent care of their patients. Nov 11, 2016.
Ameriprise Investor Relations
Skip to top site navigation. 21,930.11 ($M). 065) - (0.53) %. As of August 7, 2015 -. Minimum 20 minute delay. Minimum 20 minute delay. Q2 2015 Long Term Care Review and Other Items. Second Quarter 2015 Earnings Conference Call. Thursday, July 23, 2015. 2014 Online Annual Report. 2014 Annual Report (PDF). Q2 2015 Earnings Release. Q2 2015 Statistical Supplement. Columbia Threadneedle Investments Hires Jim Bumpus to Lead U.S. National Sales. Ameriprise Financial Declares Regular Quarterly Dividend. Electr...
Ameris Bank: your community bank for free checking, online checking and banking services.
Ameris Bank Investor Relations. Deposit and Loan Composition. News and Market Data. Sign in to your account. Ameris Bank Credit Card. Don't have internet banking? Ameris Bank Investor Relations. To learn more about how we can help you expand your financial possibilities, visit one of our locations or continue exploring our site. As of August 7, 2015. Minimum 20 minute delay. Ameris Bancorp Reports Financial Results For Second Quarter 2015. Ameris Bancorp Announces Completion Of Branch Acquisition.
Investor Relations - Amicus Therapeutics
Welcome from Chairman and CEO. Epidermolysis Bullosa (EB) Program. Patient Advocacy at Amicus. Grants and Charitable Donations. Annual Reports and Proxies. Sign Up for Email Alerts. Annual Reports and Proxies. Sign Up for Email Alerts. A passionate team with a purpose. As a monotherapy for Fabry disease, SD-101. For Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) products for Fabry disease, Pompe disease, and other Lysosomal Storage Disorders. Apr 6, 2017. Apr 3, 2017.
Amicus Therapeutics, Inc. - Investor Relations
At the forefront of therapies for rare and orphan diseases. Welcome from chairman and CEO. Protein misfolding and disease. Posters, abstracts and publications. Patient advocacy at amicus. As a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl). In combination with ERT for Pompe disease. View all ». Aug 5, 2015. Amicus Therapeutics Announces Second Quarter 2015 Financial Results and Corporate Updates. Jul 29, 2015. View all ».
Investors - Amphastar Pharmaceuticals, Inc.
Annual Reports and Proxies. We are a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and branded injectable and inhalation products. We currently manufacture and sell 15 products in the U.S. and are developing a portfolio of 13 generic and 7 branded injectable and inhalation products that primarily target markets with high technical barriers to entry. Leverage our research and development capabilities;. Amphastar...
Investors | Albany Molecular Research
Whitepapers and Trade Articles. Whitepapers and Trade Articles. Albany Molecular Research Inc. Investor Webcast: AMRI Acquires Gadea. Investor Webcast: AMRI Second Quarter Earnings. A Message from Bill Marth. Aug 4, 2015. AMRI Announces Second Quarter 2015 Results. Jul 21, 2015. AMRI to Announce Second Quarter 2015 Results. View all press releases ». Aug 25, 2015. Sep 14, 2015. View all events ». Albany Molecular Research Inc. provides global contract research and manufacturing services to the pharma...
Investor Relations | American Superconductor Corporation
Skip to main navigation. Generator and Drivetrain Solutions. Network Planning and Applications. Solar Inverter and Plant Solutions. Turbine Controls and Systems. Utility Reactive Power Solutions. Mar 30, 2018. CBS 60 Minutes segment on The Great Brain Robbery, featuring an interview with CEO, Dan McGahn. Feb 21, 2018. AMSC Announces $10 Million in D-VAR System Orders. D-VAR Systems Sales Expand into Mexico to Support Renewable Connectivity Applications and into Japan for Industrial Power Quality. AMSC to...
Investor Relations - AmTrust Financial Services
News, Financial Releases. Warranty and Specialty Risk. AmTrust is a multinational property and casualty insurer specializing in coverage for small businesses. We offer workers compensation insurance, extended warranty coverage, specialty middle-market property and casualty insurance and a host of related products and services. Gross Written Premiums. $ in Billions. Net Operating Earnings Per Share. Aug 5, 2015. Aug 4, 2015. Aug 4, 2015 at 10:00 AM ET. Jun 10, 2015 at 10:00 AM CT. News, Financial Releases.
SOCIAL ENGAGEMENT